Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YUVA-GT-F901
- Development stage
- Phase 1
- Lead developer
- Shenzhen Geno-Immune Medical Institute
- Modality
- Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
YUVA-GT-F901 is a gene therapy developed by Shenzhen Geno-Immune Medical Institute for the treatment of Hemophilia B. It involves the use of lentiviral factor IX gene modified autologous hematopoietic and mesenchymal stem cells. The therapy aims to deliver the Factor IX gene to patients, thereby enabling the production of functional Factor IX protein to correct the coagulation deficiency characteristic of Hemophilia B.
- Other names
- Lentiviral FIX Gene TherapyLentiviral factor IX gene modified autologous hematopoietic and mesenchymal stem cells
Beyond the preview
Go deeper on YUVA-GT-F901.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YUVA-GT-F901.